LIVE WEBINAR: Wednesday, February 2, 2022, 5:00 PM – 6:15 PM Eastern Time (ET)

Exploring the Current and Changing Paradigm for the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma

A CME/MOC-Accredited Virtual Event

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Wednesday, February 2nd for this CME/MOC-accredited webinar
5:00 PM – 6:15 PM ET

Christopher R Flowers, MD, MS
Chair, Professor
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Neha Mehta-Shah, MD, MSCI
Associate Professor of Medicine
Division of Oncology, Department of Medicine
Washington University School of Medicine
St Louis, Missouri

Grzegorz Nowakowski, MD
Professor of Oncology and Medicine
Vice Chair, Lymphoma Disease Group
Chair for Education
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Wednesday, February 2, 2022
5:00 PM – 6:15 PM Eastern Time
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • MODULE 1: Current Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
  • MODULE 2: Emerging Role of Polatuzumab Vedotin as a Component of First-Line Therapy for Patients with Newly Diagnosed DLBCL
  • MODULE 3: Investigational Approaches to the Care of Patients with Previously Untreated DLBCL

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of diffuse large B-cell lymphoma (DLBCL).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Apply available research findings and consider various clinical and biologic factors in the formation of evidence-based therapeutic approaches for patients with newly diagnosed DLBCL.
  • Appreciate the scientific rationale for targeting CD79b in patients with DLBCL, and review published clinical research guiding the use of polatuzumab vedotin in disease treatment.
  • Appraise emerging Phase III clinical trial data documenting the benefit of polatuzumab vedotin as a component of first-line therapy for patients with previously untreated DLBCL, and consider the implications of these findings for clinical management algorithms.
  • Compare and contrast the side effects associated with available and emerging first-line therapeutic strategies for patients with DLBCL, and formulate supportive care strategies to minimize and manage these toxicities.
  • Recall ongoing clinical research evaluating novel treatment approaches for newly diagnosed DLBCL, and counsel appropriate patients regarding the potential benefits of trial participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by an educational grant from Genentech, a member of the Roche Group.